Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China.
Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, China.
Dis Markers. 2022 Jul 5;2022:4052591. doi: 10.1155/2022/4052591. eCollection 2022.
This study is to assess the clinical value of in vitro primary cell high-efficiency expansion and high-throughput drug sensitivity screening (HEHDS) system in leukemia, and we evaluated a cohort of 121 patients with acute myeloid leukemia (AML) and 27 patients with acute lymphoblastic leukemia (ALL) using HEHDS. Bone marrow aspirates were collected from patients with leukemia. Purified leukemic cancer cells were obtained, cultured, and screened with a panel of 247 FDA-approved compounds by HEHDS technology. Ninety-six patients received HEHDS-guided therapy while 52 patients who were subjected to physician directed therapy served as controls. ALL patients who received treatment guided by HEHDS showed higher rate of complete remission (CR) than that of patients in the non-HEHDS group (90.91% vs. 56.25%). Similarly, AML patients received HEHDS-guided therapy were found to have greater CR rate, when compared with patients who received physician-directed therapy (45.88% vs. 25%). There was a significantly higher rate of CR in HEHDS-guided therapy group compared to the non-HEHDS group. The application of HEHDS could be beneficial for leukemia treatment.
本研究旨在评估体外原代细胞高效扩增和高通量药物敏感性筛选（HEHDS）系统在白血病中的临床价值，我们使用 HEHDS 对 121 例急性髓系白血病（AML）患者和 27 例急性淋巴细胞白血病（ALL）患者进行了评估。采集白血病患者的骨髓抽吸物。从纯化的白血病癌细胞中获得，并通过 HEHDS 技术用一组 247 种 FDA 批准的化合物进行培养和筛选。96 例患者接受了 HEHDS 指导的治疗，而 52 例接受医生指导治疗的患者作为对照组。接受 HEHDS 指导治疗的 ALL 患者的完全缓解（CR）率高于非 HEHDS 组（90.91% vs. 56.25%）。同样，接受 HEHDS 指导治疗的 AML 患者的 CR 率也高于接受医生指导治疗的患者（45.88% vs. 25%）。HEHDS 指导治疗组的 CR 率明显高于非 HEHDS 组。HEHDS 的应用可能有益于白血病的治疗。
